UPDATE: Wedbush Upgrades Fate Therapeutics (FATE) to Outperform

Fate Therapeutics (FATE) Showcases Positive Interim Phase 1 Data from FT596 Off-the-shelf, iPSC-derived CAR NK Cell Program for Relapsed / Refractory B-cell Lymphoma

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today showcased positive interim Phase 1 data from the Companys FT596 program for patients with relapsed / refractory B-cell lymphoma (BCL) at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition. FT596 is the Companys off-the-shelf, multi-antigen targeted, iPSC-derived natural killer (NK) cell product candidate derived from a clonal master induced pluripotent stem cell (iPSC) line engineered with three anti-tumor functional modalities: a proprietary chimeric antigen receptor (CAR) optimized for NK cell biology... More

Fate Therapeutics (FATE) FT516 Update 'Good, But Still Early' - Cowen

Cowen analyst Tyler Van Buren reiterated an Outperform rating on Fate Therapeutics (NASDAQ: FATE) after the incremental FY516 update, which the analyst said is "good, but still quite early."

The analyst commented, "The 80% ORR and 40% CRR in FT516 CAR-T naive DLBCL patients... More

Fate Therapeutics (FATE) FT516 Showing an Emerging Durability - Mizuho

Mizuho Securities analyst Mara Goldstein reiterated a Buy rating and $109.00 price target on Fate Therapeutics (NASDAQ: FATE) following the FT516 update at ASH, which showed an emerging durability probile.

The analyst commented, "FT516's update on 18 patients at ASH shows an emerging durability profile of r/r B-cell lymphoma (r/r BCL) that we see as... More

Fate Therapeutics (FATE) Reports Positive Durability of Response Data from FT516 Phase 1 Study for B-cell Lymphoma and Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to FT516

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today presented positive clinical data from the dose-escalation stage of its ongoing Phase 1 study of FT516 for patients with relapsed / refractory B-cell lymphoma (BCL) at the 63rd American Society of Hematology Annual Meeting and Exposition. FT516 is the Companys universal, off-the-shelf natural killer (NK) cell product candidate derived from a clonal master induced pluripotent stem cell (iPSC) line engineered with a novel high-affinity, non-cleavable CD16 (hnCD16) Fc receptor, which is designed to maximize antibody-dependent cellular... More

Fate Therapeutics (FATE) Highlights Positive Durability of Response Data from FT516 Phase 1 Study for B-cell Lymphoma

Fate Therapeutics, Inc. (NASDAQ: FATE) presented positive clinical data from the dose-escalation stage of its ongoing Phase 1 study of FT516 for patients with relapsed / refractory B-cell lymphoma (BCL) at the 63rd American Society of Hematology Annual Meeting and Exposition. FT516 is the Companys universal, off-the-shelf natural killer (NK) cell product candidate derived from a clonal master induced pluripotent stem cell (iPSC) line engineered with a novel high-affinity, non-cleavable CD16 (hnCD16) Fc receptor, which is designed to maximize antibody-dependent cellular cytotoxicity (ADCC), a potent anti-tumor mechanism by which NK cells recognize, bind and... More